JPH034

JPH034 is an **allosteric inhibitor of the large neutral amino acid transporter 1 (LAT1)**, also known as SLC7A5. It is being developed primarily for the treatment of **multiple sclerosis**, leveraging its ability to migrate to the brain and suppress microglia activity, which can reduce chronic inflammation. JPH034 acts as a small molecule and anti-inflammatory agent, with evidence suggesting it can modulate local inflammation in the central nervous system and promote remyelination in demyelinating lesions. The drug was discovered by Professor Yoshikatsu Kanai and colleagues at Osaka University, with development led by J-Pharma. JPH034 has received funding from the National Multiple Sclerosis Society and is protected by patents both for its substance and usage in CNS inflammatory diseases. Its development includes collaborations with Georgetown University and clinical trials targeting solid tumors and various CNS diseases[1][2][3][5][7][10].

Brand names

JPH034JPH-034JPH 034

Other names

JPH034JPH-034JPH 034OKY034OKY-034OKY 034